Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Brodalumab: Additional Phase III data

March 30, 2015 7:00 AM UTC

Additional data from the double-blind, international Phase III AMAGINE-3 trial in 1,881 patients with moderate to severe plaque psoriasis showed that 59.9% of patients receiving 140 mg subcutaneous brodalumab every 2 weeks and 79.6% of patients receiving 210 mg brodalumab every 2 weeks achieved an sPGA score of “clear” or “almost clear” at week 12, a co-primary endpoint, vs. 57.2% of patients receiving Stelara ustekinumab and 4.1% of patients receiving placebo (p<0.001 for both doses of brodalumab vs. placebo). On a secondary endpoint, 53.4% of patients receiving low-dose brodalumab and 61.2% of patients receiving high-dose brodalumab achieved a Psoriasis Symptom Inventory response at week 12 vs. 51.8% of patients receiving Stelara and 6.3% of patients receiving placebo (p<0.001 for both doses of brodalumab vs. placebo). A responder was defined as a achieving a Psoriasis Symptom Inventory total score of <=8 points with no item scores of >1 point. Data were presented at the American Academy of Dermatology meeting in San Francisco. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article